ATXS
Price
$5.65
Change
-$0.11 (-1.91%)
Updated
Jun 25 closing price
Capitalization
318.85M
46 days until earnings call
LRMR
Price
$3.25
Change
+$0.26 (+8.70%)
Updated
Jun 25 closing price
Capitalization
208.09M
42 days until earnings call
Interact to see
Advertisement

ATXS vs LRMR

Header iconATXS vs LRMR Comparison
Open Charts ATXS vs LRMRBanner chart's image
Astria Therapeutics
Price$5.65
Change-$0.11 (-1.91%)
Volume$199.71K
Capitalization318.85M
Larimar Therapeutics
Price$3.25
Change+$0.26 (+8.70%)
Volume$2.04M
Capitalization208.09M
ATXS vs LRMR Comparison Chart in %
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. LRMR commentary
Jun 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Buy and LRMR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 26, 2025
Stock price -- (ATXS: $5.65 vs. LRMR: $3.25)
Brand notoriety: ATXS and LRMR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 36% vs. LRMR: 149%
Market capitalization -- ATXS: $318.85M vs. LRMR: $208.09M
ATXS [@Biotechnology] is valued at $318.85M. LRMR’s [@Biotechnology] market capitalization is $208.09M. The market cap for tickers in the [@Biotechnology] industry ranges from $312.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileLRMR’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • LRMR’s FA Score: 1 green, 4 red.
According to our system of comparison, LRMR is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while LRMR’s TA Score has 7 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 6 bearish.
  • LRMR’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, LRMR is a better buy in the short-term than ATXS.

Price Growth

ATXS (@Biotechnology) experienced а -4.07% price change this week, while LRMR (@Biotechnology) price change was +18.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.95%. For the same industry, the average monthly price growth was +31.79%, and the average quarterly price growth was +15.79%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

LRMR is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+1.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATXS($319M) has a higher market cap than LRMR($208M). LRMR YTD gains are higher at: -16.021 vs. ATXS (-36.801). LRMR has higher annual earnings (EBITDA): -105.02M vs. ATXS (-124.4M). ATXS has more cash in the bank: 295M vs. LRMR (158M). LRMR (4.87M) and ATXS (5.06M) have identical debt. ATXS (0) and LRMR (0) have equivalent revenues.
ATXSLRMRATXS / LRMR
Capitalization319M208M153%
EBITDA-124.4M-105.02M118%
Gain YTD-36.801-16.021230%
P/E RatioN/AN/A-
Revenue00-
Total Cash295M158M187%
Total Debt5.06M4.87M104%
FUNDAMENTALS RATINGS
ATXS vs LRMR: Fundamental Ratings
ATXS
LRMR
OUTLOOK RATING
1..100
7669
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
22
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
4840
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LRMR's Valuation (22) in the null industry is somewhat better than the same rating for ATXS (59) in the Biotechnology industry. This means that LRMR’s stock grew somewhat faster than ATXS’s over the last 12 months.

LRMR's Profit vs Risk Rating (100) in the null industry is in the same range as ATXS (100) in the Biotechnology industry. This means that LRMR’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's SMR Rating (97) in the Biotechnology industry is in the same range as LRMR (100) in the null industry. This means that ATXS’s stock grew similarly to LRMR’s over the last 12 months.

LRMR's Price Growth Rating (40) in the null industry is in the same range as ATXS (48) in the Biotechnology industry. This means that LRMR’s stock grew similarly to ATXS’s over the last 12 months.

LRMR's P/E Growth Rating (100) in the null industry is in the same range as ATXS (100) in the Biotechnology industry. This means that LRMR’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSLRMR
RSI
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 11 days ago
79%
Bullish Trend 1 day ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
KGDCX18.40N/A
N/A
DWS Global Small Cap C
JLCWX72.09N/A
N/A
JHancock Fundamental Large Cap Core R6
GLCGX31.15N/A
N/A
Goldman Sachs Large Cap Gr Insghts A
KSOCX152.52N/A
N/A
Kinetics Small Cap Opportunities Adv C
PAHSX7.04N/A
N/A
PGIM Jennison NextGeneration Glb Opps A

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with ERAS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
+8.70%
ERAS - LRMR
53%
Loosely correlated
-4.83%
IMNM - LRMR
50%
Loosely correlated
-2.69%
ATXS - LRMR
50%
Loosely correlated
-1.91%
ACLX - LRMR
49%
Loosely correlated
+1.07%
ALEC - LRMR
49%
Loosely correlated
N/A
More